Literature DB >> 7682431

Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.

V Apostolopoulos1, P X Xing, J A Trapani, I F McKenzie.   

Abstract

Two murine Mabs VA1(IgG1) and VA2(IgG1) were produced against a bacterial fusion protein comprising glutathione S-transferase and five tandem repeats of the MUC1 protein. Using the immunoperoxidase staining technique, VA1 detected 46/53 and VA2 detected 48/53 breast cancers and both also reacted with a range of other human epithelial carcinomas. In addition VA1 gave weak reactions with normal breast tissues whereas VA2 was non-reactive and could be a relatively tumour specific antibody for breast cancer. The antibodies were also tested by ELISA-VA1 reacted weakly with glycosylated HMFG but strongly with deglycosylated HMFG, whereas VA2 reacted strongly with both forms of HMFG. The reactivities of the two Mabs with synthetic peptides of the MUC1 tandem repeat were used to map the epitopes recognised by VA1 (amino acids RPAPGS) and VA2 (amino acids DTRPA). The use of fusion proteins provides another means of immunisation to produce anti-tumour antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682431      PMCID: PMC1968353          DOI: 10.1038/bjc.1993.131

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Monitoring of solid phase peptide synthesis by an automated spectrophotometric picrate method.

Authors:  R S Hodges; R B Merrifield
Journal:  Anal Biochem       Date:  1975-05-12       Impact factor: 3.365

2.  Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units.

Authors:  F G Hanisch; G Uhlenbruck; J Peter-Katalinic; H Egge; J Dabrowski; U Dabrowski
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

3.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

Authors:  J Burchell; S Gendler; J Taylor-Papadimitriou; A Girling; A Lewis; R Millis; D Lamport
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  Monoclonal antibodies reactive with mucin expressed in breast cancer.

Authors:  P X Xing; J J Tjandra; S A Stacker; J G Teh; C H Thompson; P J McLaughlin; I F McKenzie
Journal:  Immunol Cell Biol       Date:  1989-06       Impact factor: 5.126

5.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

6.  A new breast carcinoma antigen defined by a monoclonal antibody.

Authors:  S A Stacker; C Thompson; C Riglar; I F McKenzie
Journal:  J Natl Cancer Inst       Date:  1985-11       Impact factor: 13.506

7.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

Authors:  S Gendler; J Taylor-Papadimitriou; T Duhig; J Rothbard; J Burchell
Journal:  J Biol Chem       Date:  1988-09-15       Impact factor: 5.157

8.  A human breast tissue-associated antigen detected by a monoclonal antibody.

Authors:  C H Thompson; S L Jones; R H Whitehead; I F McKenzie
Journal:  J Natl Cancer Inst       Date:  1983-03       Impact factor: 13.506

9.  Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen.

Authors:  J Siddiqui; M Abe; D Hayes; E Shani; E Yunis; D Kufe
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Genetic polymorphism of high molecular weight urinary glycoproteins: a comparative study in normal individuals and breast cancer patients.

Authors:  G Crocker; M R Price
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

View more
  9 in total

1.  Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

Authors:  M S Sandrin; H A Vaughan; P X Xing; I F McKenzie
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

Review 2.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

3.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

Authors:  V Karanikas; L A Hwang; J Pearson; C S Ong; V Apostolopoulos; H Vaughan; P X Xing; G Jamieson; G Pietersz; B Tait; R Broadbent; G Thynne; I F McKenzie
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

4.  MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization.

Authors:  Hye-Youn Son; Hwan-Kyu Jeong; Vasso Apostolopoulos; Chul-Woo Kim
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.298

5.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Preclinical evaluation of the novel monoclonal antibody H6-11 for prostate cancer imaging.

Authors:  Hongjun Jin; Mai Xu; Prashanth K Padakanti; Yongjian Liu; Suzanne Lapi; Zhude Tu
Journal:  Mol Pharm       Date:  2013-09-03       Impact factor: 4.939

7.  Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Authors:  Vasso Apostolopoulos; Geoffrey A Pietersz; Anastasios Tsibanis; Annivas Tsikkinis; Heleni Drakaki; Bruce E Loveland; Sara J Piddlesden; Magdalena Plebanski; Dodie S Pouniotis; Michael N Alexis; Ian F McKenzie; Stamatis Vassilaros
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

8.  Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1.

Authors:  A R Al-Yasi; M J Carroll; D Ellison; M Granowska; S J Mather; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

9.  A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1.

Authors:  R W Wilkinson; E L Ross; A E Lee-MacAry; R Laylor; J Burchell; J Taylor-Papadimitriou; D Snary
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.